Shots:

• The companies collaborated to evaluate the safety, tolerability, PK/PD & efficacy of Ascentage’s APG-1387 + Clover's SCB-313 in a P-Ib/II study in patients with advanced peritoneal carcinomatosis
• The companies are expected that a combination of SCB-313 & APG-1387 will provide a synergistic benefit to patients. Ascentage is currently conducting multiple clinical studies of APG-1387 combinations for solid tumors in China & the US.
• Clover is planning to advance SCB-313 into a P-II trial for malignant ascites in H1’22, based on P-I interim analyses & also start P-I trials of SCB-313 for bladder cancer in 2022. APG-1387 is being evaluated in a P-II study for chronic HBV infections in China

 Ref: Businesswire| Image: Ascentage